Search Results
Your search for ,twO matches 11996 pages
Showing 5451 - 5500Engage With CENTRA: ASCO’s Center for Research and Analytics
In 2017, ASCO announced the launch of its Center for Research and Analytics (CENTRA). CENTRA’s mission is to conquer cancer by generating, integrating, analyzing, and sharing oncology data to foster innovation in research and patient care. CENTRA aims to make its cancer data available to the...
New Infographic, Commentaries Highlight Role of Opioids in Managing Cancer-Related Pain
As part of ASCO’s State of Cancer Care in America initiative, the Journal of Oncology Practice recently published an infographic about opioids and cancer pain, which highlights the specific needs of patients with cancer and some of the hurdles they face in trying to access prescribed opioids to...
Northern New England Clinical Oncology Society Supports 2019 International Development and Education Award and Merit Awards
The Northern New England Clinical Oncology Society (NNECOS) is a tristate regional affiliate of ASCO serving oncology practices within Maine, New Hampshire, and Vermont. A long-time supporter of Conquer Cancer®, the ASCO Foundation, and its Young Investigator Award (YIA) program, NNECOS expanded...
Expert Point of View: Jeffrey S. Falk, MD
Jeffrey S. Falk, MD, a surgical oncologist at the Ascension Saint John Hospital in Grosse Pointe Woods, Michigan, commented on these studies of same-day mastectomy and home recovery programs: “The impetus behind these two significant quality-improvement studies was to allow patients to recover...
Studies Report Early Success With Same-Day Mastectomy and Home Recovery Programs
Patients can safely recover from mastectomy at home, according to two studies reported at the 2019 American Society of Breast Surgeons Annual Meeting.1,2 The studies examined outcomes after implementation of comprehensive postmastectomy surgical home recovery programs, showing that they...
Using Bioimpedance Spectroscopy to Prevent Progression of Lymphedema
Surveillance of women at risk for breast cancer–related lymphedema using bioimpedance spectroscopy was more effective in preventing lymphedema progression than traditional measurement of arm circumference, when each is combined with immediate compression therapy. These findings came from the...
Head and Neck Cancer Immunotherapy in Locally Advanced Disease: Clinical Trial Updates
Programmed cell death protein 1 (PD-1) inhibitors are approved for the second-line treatment of head and neck cancer and likely will be soon in the first-line treatment of locally advanced disease. According to Robert L. Ferris, MD, PhD, developments in immunotherapy for this population should be...
Alpelisib Plus Fulvestrant Approved for PIK3CA-Mutated Breast Cancer
On May 24, the U.S. Food and Drug Administration (FDA) approved the PIK3CA inhibitor alpelisib (Piqray) tablets to be used in combination with the FDA-approved endocrine therapy fulvestrant to treat postmenopausal women and men with hormone receptor–positive, HER2-negative, PIK3CA-mutated, advanced ...
Two Pediatric Trials Find Targets for Treatment-Refractory Cancers
An interim analysis of the large Pediatric MATCH trial found that 24% of children and young adolescents with cancers refractory to current treatments had been assigned to treatment with investigational targeted study agents based on genetic alterations detected in their tumors,1 which is more than...
KEYNOTE-001 Shows Long-Term Survival Benefit With Pembrolizumab in Advanced NSCLC
Before the introduction of immunotherapy with checkpoint inhibitors, the 5-year life expectancy for patients with advanced non–small cell lung cancer (NSCLC) was 5.5%. This dismal outlook has changed. Treatment with the immune checkpoint inhibitor pembrolizumab dramatically improved overall...
Expert Point of View: Yousuf Zafar, MD
At the Plenary Session, formal discussant of Dr. Davidoff’s study, Yousuf Zafar, MD, of Duke Cancer Institute, Durham, North Carolina, gave an impassioned talk about the need to address racial disparities in cancer care. “This is a nontraditional study to be selected for the ASCO Plenary Session....
ACA Increases Access to Health Care, Early Diagnosis, and Timely Treatment for Patients With Cancer
The evidence is in: the Affordable Care Act (ACA) has enabled improved access to earlier diagnosis, earlier care, and reduced racial disparities in access to care for patients with cancer, according to two studies presented at the 2019 ASCO Annual Meeting. In states that adopted Medicaid...
2019 ASCO: Study Finds Proton Therapy Reduces Adverse Events, Results in Similar Survival vs Photon Therapy
In a trial presented by Baumann et al at the 2019 ASCO Annual Meeting (Abstract 6521), patients with locally advanced cancer treated with proton chemoradiotherapy instead of traditional photon chemoradiotherapy were at a lower risk of experiencing side effects. However, cure rates were almost...
Activity of Selumetinib in Pediatric Pilocytic Astrocytoma and Low-Grade Glioma
In a phase II trial reported in The Lancet Oncology, Fangusaro et al found that the MEK1/2 inhibitor selumetinib was active in pediatric patients with recurrent, refractory, or progressive pilocytic astrocytoma with common BRAF aberrations and neurofibromatosis type 1...
2019 ASCO: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy in DLBCL
Results of the phase II Smart Start trial revealed that combination targeted therapy consisting of rituximab, lenalidomide, and ibrutinib had an 84.6% overall response rate (ORR) and 38.5% complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a...
2019 ASCO: Survey Finds 'Knowledge Gap' in Molecular Profiling Among Oncologists
A questionnaire aimed at assessing how well community oncologists understand “molecular profiling” results from tumor specimens found that 69% of participants either said they didn't know the answers or they responded incorrectly. In six different clinical scenarios, the oncologists...
William D. Tap, MD, on Soft-Tissue Sarcomas: ANNOUNCE Trial on Doxorubicin and Olaratumab
William D. Tap, MD, of Memorial Sloan Kettering Cancer Center, discusses negative study findings on doxorubicin plus olaratumab vs doxorubicin plus placebo, which showed no difference in overall survival between the two treatments in patients with advanced soft-tissue sarcomas. The manufacturer is...
Neeraj Agarwal, MD, and Thomas W. Flaig, MD, on Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy
Neeraj Agarwal, MD, of Huntsman Cancer Institute, University of Utah Health Care, and Thomas W. Flaig, MD, of the University of Colorado, discuss phase II findings on a novel predictive biomarker of response to the two accepted neoadjuvant regimens for muscle-invasive bladder cancer:...
2019 ASCO: Enfortumab Vedotin Shows Activity in Previously Treated, Locally Advanced or Metastatic Urothelial Cancer
The single-arm, phase II EV-201 trial showed treatment with enfortumab vedotin—an agent targeting Nectin-4, a protein found in 97% of urothelial cancers—produced responses in 44% of patients with locally advanced or metastatic forms of urothelial cancer. Patients had previously been...
2019 ASCO: Expansion of Clinical Trial Inclusion Criteria in Patients With Advanced NSCLC
A study that examined 10,500 health records of patients with advanced non–small cell lung cancer from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria—as proposed by ASCO and Friends of Cancer Research in 2017—would nearly double...
2019 ASCO: POLO: Maintenance Olaparib in Germline BRCA-Mutated Pancreatic Cancer
The randomized phase III POLO trial found that maintenance therapy with the poly (ADP-ribose) polymerase inhibitor olaparib significantly delayed the progression of metastatic pancreatic cancer in patients with germline BRCA gene mutations compared with placebo (median...
2019 ASCO: Medicaid Expansion and Time to Treatment in African American Patients Compared to White Patients With Cancer
Previous racial disparities in timely cancer treatment between African American and white patients were reduced in states where Medicaid access was expanded under the Affordable Care Act (ACA), according to a new analysis of electronic health records from for 30,000 patients. The study, based on...
2019 ASCO: Effect of ACA Implementation on Diagnosis and Treatment of Ovarian Cancer in Women Under 65
An analysis of data from the National Cancer Database found that after implementation of the 2010 Affordable Care Act (ACA), ovarian cancer was diagnosed and treated at an earlier stage among women younger than age 65. More women also received treatment within 30 days of diagnosis, thereby...
2019 ASCO: Vincristine and Irinotecan With or Without Temozolomide in Relapsed or Refractory Rhabdomyosarcoma
In the European phase II VIT-091 trial, researchers examined the efficacy of the combination of vincristine and irinotecan with or without the addition of temozolomide in children and adults with relapsed or refractory rhabdomyosarcoma. Their results were presented by Defachelles et al at the 2019...
2019 ASCO: Differences in End-of-Life Quality Measures Across U.S. Cancer Centers
In a study presented by Wasp et al at the 2019 ASCO Annual Meeting (Abstract 6507) studying variation in end-of-life care across cancer centers in the United States, researchers found quality of care was lower at centers that served a greater concentration of minorities. However, end-of-life care...
Ahead of the Curve, Breast Cancer Specialist Advocates Prevention Through Exercise and Lifestyle
Breast cancer specialist Julie Gralow, MD, FASCO, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, has a straightforward philosophy about her career: “Cancer is about living, not dying. I enjoy helping my patients with breast cancer take control of their health through leading-edge ...
Never Forgetting His Roots Helps Surgical Oncologist Better Connect With His Patients
Raja M. Flores, MD, grew up in New York’s Meatpacking District, a rough West Side neighborhood, light years before its gentrification into a hip commercial area, home to the Whitney Museum of American Art, high-end designer clothing stores and chic bars, and a stretch of the High Line (an...
A Lifetime Dedicated to Patients With Lung Cancer
Former ASCO President Paul Bunn, Jr, MD, FASCO, was born at the New York Hospital, the second oldest hospital in New York City and the third oldest in the nation. He grew up in DeWitt, New York, an eastern suburb of Syracuse, and went through the public-school system graduating from...
A Brilliant Career in Oncology Decided on a Coin Toss
Rajendra Achyut Badwe, MBBS, MS, was born and reared in the sprawling city of Mumbai, the most populous city in India. “My grandmother was a matron in an infectious disease hospital. At that time, smallpox was a serious issue, and the patient care challenges were momentous. She taught me the value...
Polatuzumab Vedotin and Immunochemotherapy in Previously Untreated Diffuse Large B-Cell Lymphoma
As reported in The Lancet Oncology, Tilly et al found that the combination of polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, with immunochemotherapy showed high response rates in the phase II portion of a phase I/II study in previously...
Stand Up To Cancer Names Grant Recipients of ‘Innovation in Collaboration’
The Phillip A. Sharp Awards for Innovation in Collaboration, are named for Phillip A. Sharp, PhD, Nobel Laureate, and molecular biologist at Massachusetts Institute of Technology, in recognition of his emphasis on collaboration across research institutions and different teams. Stand Up To Cancer...
Radiation Oncologist Lori J. Pierce, MD, FASCO, FASTRO, Enjoys Balancing Administrative and Clinical Roles
Lori J. Pierce, MD, FASCO, FASTRO, grew up in Washington, DC, and moved with her family to Philadelphia while in high school. She still considers the fast-paced DC–Philadelphia corridor her home, but her passion for a career in medicine, in part, took seed in a small town located in North...
Breast Cancer Specialist Focuses on Educational Side of Oncology, Connecting Patients With Cancer Around the World
Internationally renowned breast cancer specialist Daniel A. Vorobiof, MD, was born in Santa Fe, Argentina, a province in the northeastern region of the country that is prone to catastrophic flooding. Asked about any early influences in his desire to pursue a career in medicine, Dr. Vorobiof...
Cancer Researcher Continues to Push the Envelope in Immunotherapy to Help Patients Live Longer
Nationally regarded cancer immunologist Padmanee Sharma, MD, PhD, was born and reared in Georgetown, Guyana, on South America’s North Atlantic coast, noted for being the only South American country in which English is the official language. Her parents were descendants of indentured immigrants...
FDA Oncology Drug Approvals Granted Between May 21, 2018 and May 14, 2019
Over the past year (May 2018–May 2019), the U.S. Food and Drug Administration (FDA) granted approval and accelerated approval to a number of new oncology drugs and biosimilars. Here we list the new FDA-approved labels and indications. AVELUMAB (BAVENCIO) and AXITINIB (INLYTA) has been approved as a ...
FDA Approves Lenalidomide in Combination for Previously Treated Follicular and Marginal Zone Lymphomas
Today, the U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid) in combination with a rituximab product for previously treated follicular and marginal zone lymphoma. AUGMENT and MAGNIFY Trials Approval was based on two clinical trials: AUGMENT and MAGNIFY. In AUGMENT, 358...
FDA Approves Alpelisib in Combination With Fulvestrant for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
On May 24, the U.S. Food and Drug Administration (FDA) approved alpelisib (Piqray) tablets to be used in combination with the FDA-approved endocrine therapy fulvestrant to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2...
AYA Survivors Should Be Allowed to Participate in Adult Clinical Trials
When strangers ask me how many children I have, I’m not quite sure how to respond. Do I still have four children even though one has died? A year and a half after my son Brent’s death, at the age of 18, from complications of acute myeloid leukemia (AML), I’m still struggling with knowing the...
Unlocking the Secrets of the Immune System, Story by Story
The story of immunotherapy is one of the most interesting and provocative in medical history. William B. Coley, MD, first harnessed the immune system against cancer in the late 19th century by injecting mixtures of live and inactivated bacteria into patients’ tumors. For various reasons,...
Lifestyle Modifications and Screening of Patients at High Risk Can Reduce Deaths From Pancreatic Cancer
After disclosing that he had been diagnosed with stage IV pancreatic cancer, Alex Trebek, longtime host of the popular television game show Jeopardy!, vowed that he would beat the disease despite the low associated survival rate. His statement has brought pancreatic cancer back into the public...
NCCN Recognizes Five Individuals for Achievements in Cancer Care
THE NATIONAL Comprehensive Cancer Network® (NCCN®) has announced the recipients of a series of awards honoring individuals whose contributions have fueled progress in improving and facilitating quality, effective, efficient, and accessible cancer care over the past year. They are Timothy J....
Pancreatic Cancer Collective Funds Two Research Teams Using AI to Identify High-Risk Populations
THE PANCREATIC Cancer Collective, which is the strategic partnership of the Lustgarten Foundation and Stand Up To Cancer (SU2C), recently announced that it has awarded $1 million grants to each of 2 projects that are using artificial intelligence (AI) computational approaches to identify high-risk...
City of Hope Awarded $7.5 Million for Research in Cutaneous T-Cell Lymphoma
CITY OF HOPE recently received $7.5 million in grant awards to study the rare blood cancer cutaneous T-cell lymphoma. The National Cancer Institute (NCI) awarded two grants valued at $6.3 million over 5 years to City of Hope’s Steven Rosen, MD, and Christiane Querfeld, MD, PhD, so they can develop...
Otis W. Brawley, MD, MACP, FASCO: Doctor, Policy Advocate, Writer, and Champion of the Underserved
In this installment of Living a Full Life, guest editor Jame Abraham, MD, FACP, spoke with Otis W. Brawley, MD, MACP, FASCO, a global leader in cancer research and health disparities. Dr. Brawley, who served as Chief Medical and Scientific Officer for the American Cancer Society (ACS) and...
Ghanaian Oncologist Yehoda M. Martei, MD, Seeks Ways to Improve Outcomes in the Developing World
Breast cancer remains the most commonly diagnosed cancer among women globally. Due to a lack of early interventions, most women in low- and middle-income countries have advanced disease at the time of diagnosis, conferring a grim prognosis. Yehoda M. Martei, MD, of the Department of Medicine,...
Uniting the Global Cancer Community to Reduce Deaths From Noncommunicable Diseases
It has been well documented that noncommunicable diseases, including cancer, cardiovascular disease, and diabetes, now pose the greatest health threat to people living in low- and middle-income countries, surpassing infectious diseases like HIV/AIDS as the leading cause of death and disability.1...
ASH President Comments on Medicare Proposal for CAR T-Cell Therapy
Recently, the Centers for Medicare & Medicaid Services (CMS) proposed to improve the reimbursement currently given to hospitals that provide chimeric antigen receptor (CAR) T-cell therapy to patients with blood cancer as part of the Fiscal Year 2020 Inpatient Prospective Payment System...
How Cancer Affects Adolescents and Young Adults
The statistics are alarming: according to the National Cancer Institute (NCI), about 70,000 adolescents and young adults (AYAs) are diagnosed with cancer each year1—a recent report by the University of California put that figure at 87,000.2 Although overall cancer survival rates continue to improve ...
New Radiation Options for Localized Prostate Cancer May Improve Patient Outcomes
External-beam radiation therapy (EBRT) is a standard treatment option for men with localized prostate cancer and confers long-term prostate cancer control outcomes equal to radical prostatectomy. Technologic advances in imaging and computing during the past 20 years have led to a number of...
AIM at Melanoma Foundation Opens First Melanoma Tissue Bank in the United States
The AIM at Melanoma Foundation recently announced the grand opening of the first branch of the International Melanoma Tissue Bank Consortium (IMTBC) at the Hillman Cancer Center, University of Pittsburgh Medical Center (UPMC). The Pittsburgh site is the first of six global locations of the...
